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270Chronic lung disease (CLD) is
common in patients with severe
aortic stenosis (AS) (1). Because
lung disease is considered a risk
for mortality and morbidity after
surgical aortic valve replacement
(SAVR) (2), many patients with
combined AS and CLD are
referred for the less invasive
transcatheter approach. The in-
cidence of CLD in large trans-
catheter aortic valve replacement
(TAVR) registries is 21% to 43%
(3–10), while lung disease is sug-
gested to be a predictor for lower
survival after TAVR (10–12).
TAVR is superior to medical
treatment in patients considered
unsuitable for conventional sur-
gery and is associated with similar
long-term results in surgicalhigh-risk patients when compared with SAVR (5,6).
However, the outcome of patients with CLD undergoing
TAVR has not been systematically studied and no
comparison has been made between TAVR and alternative
treatment strategies in CLD patients.
The current study has 2 main objectives: 1) to evaluate
CLD impact on clinical outcomes following TAVR, or
standard therapy; and 2) to identify predictors for poor
outcome following TAVR in patients with CLD. Patients
from both the randomized controlled trial (RCT) and
nonrandomized continued access (NRCA) registry of the
PARTNER (Placement of AoRTic TraNscathetER Valve)
trial were included in the analysis.Methods
Study design. The design and initial results of the
PARTNER trial have been previously published (5,6,13,14).
Brieﬂy, RCT enrolled patients with severe symptomatic AS
who were either high risk for surgical AVR (Cohort A) or
were deemed inoperable (Cohort B). Patients in the high-risk
arm were randomized between surgery and TAVR via the
transfemoral or transapical approach depending on trans-
femoral access suitability. Patients in the inoperable arm were, Medtronic, Volcano, Eli Lilly, Daiichi Sankyo,
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Following completion of the RCT, an NRCA protocol
allowed treatment of both Cohort A and Cohort B
patients with TAVR. Inclusion/exclusion criteria, data
collection, and monitoring were the same in both the
NRCA and RCT; core laboratories for data analysis like-
wise remained unchanged. All patients in both the NRCA
and RCT were presented and adjudicated as appropriate
candidates during conference calls with the executive
committee and other investigators. These presentations
included patients’ baseline characteristics as well as data on
lung disease and its severity, including pulmonary function
test results and data on oxygen dependency. For each
patient included in the PARTNER trial, the Society of
Thoracic Surgeons (STS) score was calculated. Patients
were deﬁned and stratiﬁed accordingly with regard to lung
disease severity: none; mild: 1-s forced expiratory volume
(FEV1) 60% to 75% of predicted, and/or on chronic
inhaled or oral bronchodilator therapy; moderate: FEV1
50% to 59% of predicted, and/or on chronic steroid
therapy aimed at lung disease; and severe: FEV1 <50%
predicted, and/or room air partial pressure of O2 <60 mm Hg
or room air partial pressure of CO2 >50 mm Hg. A
baseline 6-min walk test (6MWT) was performed
according to the American Thoracic Society guidelines
(15). Study endpoints were reported according to Valve
Academic Research Consortium deﬁnitions (16). All
adverse events were adjudicated by an independent clinical
events committee. Independent core laboratories analyzed
all echocardiograms and electrocardiograms. All data were
sent for analysis to an independent academic biostatistics
group. The PARTNER study was approved by the
institutional review board at each participating site, and
all patients provided written informed consent.
Patient populations. For the purpose of the present study,
2 different analyses were performed using subsets of patients
from the PARTNER trial. In order to assess the effect of
CLD on outcomes following TAVR or standard therapy,
a population of CLD patients from the randomized arm of
the PARTNER trial was analyzed (Fig. 1A). In order to
assess the impact of CLD on outcomes following TAVR, all
patients undergoing TAVR in either the RCT or NRCA
were stratiﬁed by disease clinical severity and analyzed
(Fig. 1B).royalty/intellectual property rights with Apica. Dr. Makkar has received research
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Figure 1
Flow Chart of the Study Design and
Patient Populations
(A) Population of chronic lung disease patients included in the randomization
arms. (B) Population of patients that underwent transcatheter aortic valve
replacement (TAVR) included in either the randomization arms or the non-
randomized continued access. SAVR ¼ surgical aortic valve replacement;
TA ¼ transapical; TF ¼ transfemoral.
JACC Vol. 63, No. 3, 2014 Dvir et al.
January 28, 2014:269–79 TAVR in Patients With Chronic Lung Disease
271CLD POPULATION. Of the 1,057 patients enrolled in the
PARTNER RCT, a total of 454 patients with CLD were
identiﬁed: 287 patients from the high-risk arm (Cohort A)
and 167 from the inoperable arm (Cohort B) (Fig. 1A). In
these patients, comparison of treatment strategies between
TAVR and control was performed: TAVR versus SAVR in
Cohort A patients and TAVR versus standard therapy in
Cohort B patients. Study endpoints included 30-day rates of
all-cause death, cardiovascular death, major stroke, major
vascular complication, major bleeding, and acute kidney
injury. One- and 2-year rates of all-cause death, cardiovas-
cular death, repeat hospitalization, and the composite of
death or repeat hospitalization were also collected.
TAVR POPULATION. All patients who underwent TAVR in
either the RCT or the NRCA were pooled (n ¼ 2,553) and
stratiﬁed according to presence of CLD: patients without
CLD (n ¼ 1,445) were compared to those with CLD
(n ¼ 1,108). CLD patients were further divided into
non–oxygen-dependent (n ¼ 836) and oxygen-dependent
(n ¼ 272) (Fig. 1B). Baseline characteristics were comparedbetween patients with and without CLD, as well as
between non–oxygen-dependent and oxygen-dependent
CLD patients. Study endpoints included 30-day and 1-year
New York Heart Association (NYHA) functional class,
all-cause death, cardiovascular death, repeat hospitalization,
and combined death or repeat hospitalization. In the group
of CLD patients that underwent TAVR, independent
correlates for 1-year death were evaluated.
Statistical analysis. All analyses were performed with data
from the as-treated patients in the 2 patient populations
studied: CLD patients included in the randomization arms;
and patients who underwent TAVR in either the RCT arms
or in the NRCA. NRCA patients were not included in the
evaluation of the CLD population between TAVR and
control in order to keep these groups as closely matched as
possible and to maintain the integrity of randomization.
Continuous variables are summarized as mean  SD or as
medians and quartiles, as appropriate, and were compared
using Student’s t test or Mann-Whitney rank sum test
accordingly. Categorical variables were compared by the
chi-square or the Fisher exact test. Survival curves for time-
to-event variables were constructed using Kaplan-Meier
estimates, while comparisons relied on the log-rank test.
Outcomes were compared for up to 2 years in an analysis
that included only patients from the RCT and up to 1 year
when patients from NRCA were included. Cox multivari-
able regression analysis was performed to identify indepen-
dent correlates for 1-year survival in CLD patients who
underwent TAVR. The multivariable model was built by
selecting baseline variables of clinical interest and/or those
that satisﬁed the entry criterion of p < 0.05 in a univariate
analysis: patient age, sex, body mass index (BMI), STS
score, renal failure, liver disease, peripheral vascular disease,
diabetes mellitus, pulmonary artery pressure, aortic valve
gradient, 6MWT, and oxygen dependency (vs. non–oxygen
dependency). A 2-sided alpha level of 0.05 was used for all
superiority testing. All statistical analyses were performed
using SAS software, version 9.2 (SAS Institute, Cary, North
Carolina).
Results
CLD population. TAVR VERSUS MEDICAL THERAPY. CLD
patients included in the inoperable arm (Cohort B) were
treated by either transfemoral TAVR (n ¼ 72) or by stan-
dard therapy (n ¼ 95) (Fig. 1A). Baseline characteristics
were similar between groups (Table 1). The rate of all-cause
death in inoperable CLD patients undergoing TAVR was
12.5% at 30 days (Table 2) After 2-year follow-up, all-cause
death was lower in CLD patients undergoing TAVR versus
medical therapy (52.0% vs. 69.6%, p ¼ 0.04) (Fig. 2A).
Similarly, repeat hospitalization and the composite of death
or repeat hospitalization were lower in the TAVR group
(Fig. 2B).
TAVR VERSUS SAVR. CLD patients included in the high-risk
arm (Cohort A) were treated by either TAVR (n ¼ 149;
Table 1 Baseline Characteristics of CLD Patients Included in a Randomization: TAVR Versus Control
Cohort A Cohort B
TAVR
(n ¼ 149)
SAVR
(n ¼ 138) p Value
TAVR
(n ¼ 72)
Std Tx
(n ¼ 95) p Value
Age, yrs 81.6  7.0 82.9  6.6 0.17 81.0  7.8 81.1  8.0 0.86
Men, % 60.4 60.9 0.94 47.2 44.2 0.70
STS score, % 11.9  2.9 12.0  3.5 0.44 11.7  6.0 11.6  4.8 0.52
Logistic EuroSCORE 29.1  15.8 31.0  16.7 0.33 26.5  17.0 29.0  18.6 0.42
NYHA functional class IV 61.7 53.6 0.16 51.4 55.8 0.57
Coronary artery disease 77.2 75.4 0.72 63.9 66.3 0.74
Previous coronary bypass surgery 43.6 42.0 0.78 29.2 30.5 0.85
Previous percutaneous coronary intervention 38.1 29.2 0.11 22.2 18.9 0.60
Previous balloon aortic valvuloplasty 14.1 10.9 0.41 12.5 20.0 0.20
Cerebral vascular disease 35.9 27.7 0.15 24.6 25.0 0.96
Peripheral vascular disease 48.6 43.0 0.34 34.7 30.5 0.57
Creatinine >2 mg/dl 17.4 15.2 0.61 15.3 14.7 0.92
Permanent pacemaker 19.5 23.2 0.44 12.5 18.9 0.26
Liver disease 4.0 3.6 0.86 1.4 2.1 1.0
Aortic valve area, cm2 0.68  0.21 0.65  0.19 0.17 0.66  0.19 0.68  0.23 0.72
Mean aortic valve gradient, mm Hg 42.7  15.0 42.1  13.6 0.87 43.7  14.8 41.8  16.0 0.36
LVEF, % 53.0  13.7 52.7  13.6 0.81 53.3  12.5 50.1  15.2 0.34
Values are mean  SD or %.
CLD ¼ chronic lung disease; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; SAVR ¼ surgical aortic
valve replacement; Std Tx ¼ standard therapy; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
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27269.1% transfemoral, 30.9% transapical) or by SAVR (n¼ 138)
(Fig. 1A). There was no signiﬁcant difference in
baseline characteristics between groups (Table 1). Long-
term survival did not differ signiﬁcantly between the
TAVR and the SAVR groups (35.2% vs. 33.6%, p ¼ 0.92)
(Fig. 2C). After 30 days, the TAVR group had more major
vascular complications and less major bleeding events
(Table 2). A comparison of 6-month survival among trans-
femoral TAVR, transapical TAVR, and SAVR patients inTable 2 Clinical Outcomes of CLD Patients Included in the Randomi
Cohort
TAVR
(n ¼ 149)
SAV
(n ¼ 1
30 days
Death from any cause 7.4 10.
Death from cardiovascular cause 5.4 2.
Major stroke 1.3 0
Major vascular complication 8.7 0.
Acute kidney injury-renal replacement therapy 5.4 5.
Major bleeding 10.1 20.
1 year
Death from any cause 25.0 26.
Death from cardiovascular cause 10.6 8.
Repeat hospitalization 17.5 18.
Death from any cause or repeat hospitalization 34.5 37.
2 years
Death from any cause 35.2 33.
Death from cardiovascular cause 11.6 10.
Repeat hospitalization 24.2 21.
Death from any cause or repeat hospitalization 47.2 44.
Values are %.
Abbreviations as in Table 1.Cohort A showed a trend in favor of the transfemoral
approach, which was not statistically signiﬁcant (12.6% vs.
17.6% vs. 23.2%, p ¼ 0.12). By 2-year follow-up, however,
survival rates were similar (36.1% vs. 33.6% vs. 33.5%,
p ¼ 0.99) (Figs. 2E and 2F).
TAVR population. A total of 2,553 patients who under-
went TAVR and were included in the RCT or in the NRCA
were pooled. Compared to patients without CLD, CLD
patients were younger, had higher STS scores, higherzation: TAVR Versus Control
A Cohort B
R
38) p Value
TAVR
(n ¼ 72)
Std Tx
(n ¼ 95) p Value
9 0.30 12.5 2.1 0.008
9 0.30 11.1 2.1 0.02
0.50 2.9 0 0.10
7 0.002 13.9 2.1 0.003
1 0.91 4.4 3.2 0.68
3 0.02 19.6 5.4 0.003
9 0.60 37.5 52.2 0.12
6 0.61 20.3 31.4 0.27
5 0.81 24.6 52.3 0.004
0 0.57 48.6 69.9 0.03
6 0.92 52.0 69.6 0.04
0 0.63 25.5 44.9 0.06
6 0.87 36.8 67.5 <0.001
3 0.87 61.6 85.7 0.003
Figure 2 Time-to-Event Curves in CLD Patients Included in the Randomization Arms
(A and B) Comparison of transcatheter aortic valve replacement (TAVR) and medical therapy in Cohort B chronic lung disease (CLD) patients. (C and D) Comparison of TAVR
and surgical aortic valve replacement (SAVR) in Cohort A CLD patients. (E and F) Comparison of transfemoral (TF) TAVR, transapical (TA) TAVR and SAVR in Cohort A CLD patients.
CI ¼ conﬁdence interval.
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273pulmonary artery pressure, NYHA functional class IV,
peripheral vascular disease, cerebrovascular disease, and lower
permanent pacemaker implantation (Table 3). At 1-yearfollow-up, CLD patients had a higher mortality rate than
did patients without CLD (23.4% vs. 19.6%, p ¼ 0.02) and
a higher rate of combined mortality or repeat hospitalization
Table 3 Baseline Characteristics of TAVR Patients
No CLD
(n ¼ 1445)
CLD
(n ¼ 1108) p Value
Non–Oxygen-Dependent CLD
(n ¼ 836)
Oxygen-Dependent CLD
(n ¼ 272) p Value
Age, yrs 85.8  6.8 82.7  7.2 <0.0001 83.3  7.1 80.7  7.2 <0.0001
Men 50.8 54.4 0.07 56.6 47.8 0.01
STS score 11.2  4.4 11.9  4.1 <0.0001 11.8  3.7 12.2  4.9 0.46
Logistic EuroSCORE 25.9  16.0 27.2  16.5 0.052 28.9  16.8 23.8  14.7 <0.0001
Considered inoperable 7.1 6.5 0.53 4.2 13.6 <0.0001
NYHA functional class IV 44.3 49.5 0.009 47.6 55.5 0.02
Coronary artery disease 78.7 76.6 0.22 79.0 69.1 0.0008
Previous coronary bypass surgery 44.3 40.6 0.06 44.2 29.4 <0.0001
Previous percutaneous coronary intervention 44.3 40.6 0.06 41.8 35.2 0.052
Previous balloon aortic valvuloplasty 22.2 24.8 0.12 24.3 26.5 0.47
Cerebral vascular disease 24.6 28.4 0.03 29.5 25.1 0.17
Peripheral vascular disease 40.9 45.3 0.03 48.2 36.2 0.0006
Renal disease, creatinine >2 mg/dl 16.7 16.4 0.84 17.6 12.9 0.07
Permanent pacemaker 23.1 19.3 0.02 20.9 14.3 0.02
Liver disease 2.4 3.1 0.26 3.4 2.2 0.35
Mean pulmonary artery pressure, mm Hg 28.6  10.6 29.9  9.8 0.0007 29.4  9.9 31.5  9.5 0.004
Aortic valve area, cm2 0.64  0.19 0.66  0.19 0.001 0.66  0.18 0.67  0.21 0.53
Mean aortic valve gradient, mm Hg 44.3  14.5 43.2  14.1 0.10 43.1  14.2 43.6  13.7 0.38
Mean LVEF, % 52.0  13.0 53.1  12.8 0.03 53.1  12.5 52.7  13.2 0.94
Values are mean  SD or %.
Abbreviations as in Table 1.
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274(34.8% vs. 30.8%, p ¼ 0.02) (Table 4, Fig. 3). Compared to
non–oxygen-dependent CLD, those who were oxygen
dependent were younger, were more often female, and had
higher pulmonary artery pressure and NYHA functional
class IV rates (Table 3). Additionally, oxygen-dependent
CLD patients had lower logistic EuroSCOREs and lower
rates of coronary artery disease, previous bypass surgery,
peripheral vascular disease, and permanent pacemaker. At
1-year follow-up, oxygen-dependent CLD patients had
a higher mortality rate compared to those with non–oxygen
dependent CLD (29.7% vs. 21.4%, p ¼ 0.004) and a higher
rate of the combined endpoint of death or repeat hospitali-
zation (42.5% vs. 32.3%, p ¼ 0.002) (Table 4).
The functional status of patients after TAVR was
compared according to CLD clinical severity at baseline.
Patients were divided into 3 groups: no CLD, non–oxygen-
dependent CLD, and oxygen-dependent CLD (Fig. 4). AtTable 4 Clinical Outcomes of TAVR Patients
No CLD
(n ¼ 1445)
CLD
(n ¼ 1108) p
30 days
Death from any cause 5.5 6.7
Death from cardiovascular cause 3.8 4.9
1 year
Death from any cause 19.6 23.4
Death from cardiovascular cause 9.0 10.2
Repeat hospitalization 16.5 19.7
Death from any cause or repeat hospitalization 30.8 34.8
Values are %.
Abbreviations as in Table 1.baseline, 30 days and 1 year of follow-up, these 3 groups
differed signiﬁcantly: patients without CLD had the best
functional class (Fig. 4). CLD patients who were oxygen
dependent had worse functional status than those in the
other groups, which was manifested by higher rates of death
or poor functional status (NYHA functional class III/IV) at
both 30 days (45.1%) and 1 year (49.6%; p <0.0001 for
both) (Fig. 4).
The following baseline parameters were identiﬁed in
CLD patients undergoing TAVR as independent predic-
tors for 1-year all-cause mortality: short 6MWT, oxygen
dependency, renal disease, low BMI, higher mean
pulmonary artery pressure, and higher aortic valve gradient
(Table 5). Baseline 6MWT in CLD patients undergoing
TAVR was negatively correlated with both 1-year all-cause
mortality and 1-year noncardiovascular mortality (p ¼
0.02, p < 0.001, respectively). CLD patients with poorValue
Non–Oxygen-Dependent CLD
(n ¼ 836)
Oxygen-Dependent CLD
(n ¼ 272) p Value
0.23 6.1 8.5 0.17
0.19 4.2 7.0 0.06
0.02 21.4 29.7 0.004
0.26 9.4 12.4 0.12
0.054 18.0 24.8 0.02
0.02 32.3 42.5 0.002
Figure 3 Time-to-Event Curves in Patients Undergoing Transcatheter Aortic Valve Replacement
Comparison of all-cause death (A) and the composite of death or rehospitalization (B) between chronic lung disease (CLD) and non-CLD patients. CI ¼ conﬁdence interval.
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275baseline mobility (6MWT <50 m) had a 4.9 higher rate
of noncardiovascular death during the ﬁrst year after the
procedure (20.9% vs. 4.3% in those with 6MWT >200
m). In 70.4% of patients with poor mobility who died
during the ﬁrst year after TAVR, the cause of death was
noncardiovascular; 68.8% of patients who died from
respiratory insufﬁciency during that 1-year period hadFigure 4 Symptom Status
Comparison at baseline, 30 days, and 1 year post–transcatheter aortic valve replacement
with oxygen-dependent CLD. NYHA ¼ New York Heart Association.CLD at baseline. Pulmonary hypertension severity in
CLD patients undergoing TAVR was correlated at 1 year
with both all-cause mortality and cardiovascular mortality
(p ¼ 0.006, p ¼ 0.04, respectively).
A score for predicting all-cause death in CLD patients
undergoing TAVR included the previous independent
parameters. The PBOSS score (scale 0 to 5 points) includes(TAVR) among those without CLD, those with non–oxygen-dependent CLD, and those
Table 5
Baseline Correlates for 1-Year All-Cause Death in
Patients With CLD Post TAVR
Hazard Ratio (95% CI) p Value
Univariate analysis
Patient age, yrs 1.01 (0.98–1.05) 0.12
Male 1.07 (0.94–1.21) 0.31
Liver disease 0.60 (0.30–1.22) 0.16
Peripheral vascular disease 1.00 (0.86–1.17) 0.99
Diabetes Mellitus 1.18 (0.95–1.51) 0.13
Poor patient mobility* 1.69 (1.28–2.47) <0.0001
Oxygen dependency 1.39 (1.12–1.74) 0.004
Renal diseasey 1.35 (1.01–1.81) 0.05
Body mass index, kg/m2 0.95 (0.91–0.99) 0.0002
Mean pulmonary artery pressure
(per 10-mm Hg increase)
3.11 (1.48–5.70) 0.003
Mean aortic valve gradient
(per 10-mm Hg increase)
0.97 (0.95–0.99) 0.004
Multivariate Cox regression analysis
Poor patient mobility* 1.67 (1.23–2.22) 0.0009
Oxygen dependency 1.44 (1.05–1.97) 0.02
Renal diseasey 1.43 (1.00–2.05) 0.049
Body mass index, kg/m2 0.97 (0.95–0.99) 0.004
Mean pulmonary artery pressure
(per 10-mm Hg increase)
1.26 (1.10–1.45) 0.0008
Mean aortic valve gradient
(per 10-mm Hg increase)
0.99 (0.97–1.00) 0.01
*6-min walk test <50 m. yCreatinine >2 mg/dl.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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>25 mm Hg: 1 point), BMI (<21 kg/m2: 1 point), oxygen
dependency (1 point), stress (6MWT <50 m: 2 points; 50
to 199 m: 1 point). Figure 5 illustrates the trend of 1-year
all-cause death in CLD patients undergoing TAVR
according to the PBOSS score (p < 0.001).Figure 5 PBOSS Risk Score
One-year all-cause death rates post-transcatheter aortic valve replacement (TAVR)
among patients with chronic lung disease according to their PBOSS score at
baseline (scale 0 to 5): pulmonary hypertension (mean pulmonary pressure
25 mm Hg: 1 point), body mass index (<21 kg/m2: 1 point), oxygen dependency
(1 point), and stress (6-min walk test 50 to 199 m: 1 point; <50 m: 2 points).Discussion
TAVR is associated with signiﬁcant clinical improvements in
high-risk severe AS patients (17–19). However, little was
known about whether severe AS patients with CLD expe-
rience a similar improvement following the procedure. The
current trial reached the following ﬁndings: 1) clinical
improvement after TAVR in the general population of CLD
patients did not differ signiﬁcantly from patients without
CLD; and 2) TAVR was superior to medical therapy in
patients considered inoperable and had similar clinical
outcomes when compared to SAVR in operable high-risk
patients. However, 2 subgroups of CLD patients had rela-
tively poor outcomes after TAVR: oxygen-dependent CLD
patients, only half were alive with good functional status at
1-year follow-up; and CLD patients with poor mobility at
baseline. Relatively immobile CLD patients had higher rates
of death after TAVR, mostly secondary to noncardiovascular
etiologies.
Clinical improvement of CLD patients after aortic valve
implantation. CLD is traditionally considered a risk factor
for mortality and signiﬁcant morbidity after cardiac surgery
and it is suggested that many CLD patients do not improve
clinically after SAVR (20–22). Nevertheless, several studies
suggest that in the current TAVR era, CLD patients
referred for SAVR improve equally after the procedure as do
patients without CLD (23,24). Similarly, there is no
consensus regarding clinical improvement of CLD patients
after TAVR; and lung disease is a common cause for
deferring interventions (25,26). Several trials have suggested
that baseline CLD is a predictor for mortality after TAVR
(9–12) and pulmonary complications have emerged as
a common etiology for noncardiac cause of death in patients
undergoing TAVR (27). CLD was also found to be
a predictor for acute kidney injury and stroke after TAVR
(28,29). Nevertheless, several large trials did not ﬁnd
CLD to be an independent predictor for mortality after
TAVR.(4,14,30). According to the current analysis,
high-risk CLD patients with severe AS improve after
TAVR similarly to those without CLD. Additionally, the
current analysis revealed that the correlates for 1-year
mortality in CLD patients after TAVR are different than
those seen in the general population of patients undergoing
TAVR (14), and include short 6MWT, oxygen dependency,
high pulmonary artery pressure, renal disease, and low BMI.
In the TAVR population from the PARTNER trial, it
should be noted that although lung disease patients were on
average 3.1 years younger than those without CLD, their
STS scores were signiﬁcantly higher.
Poor mobility of CLD patients. Poor exercise capacity of
CLD patients is considered a signiﬁcant marker for
increased mortality, a stronger marker than the degree of
airway obstruction (31–33). 6MWT, when performed
before several interventions, was used to identify patients at
high risk for post-operative complications (34–36). Gait
speed was also found to be a strong independent correlate
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January 28, 2014:269–79 TAVR in Patients With Chronic Lung Disease
277for mortality in patients undergoing cardiac surgery (37).
In severe AS patients, a poor 6MWT was found to be
a marker for long-term mortality in patients with low-ﬂow
low-gradient AS and in those undergoing SAVR (38,39).
The 6MWT was also examined in patients undergoing
TAVR as a tool to assess clinical improvement (19,40).
Our study reveals that a poor baseline 6MWT result in
a CLD patient is associated with increased mortality
after TAVR. Speciﬁcally, there is a signiﬁcant correlation
between 6MWT distance at baseline and non-
cardiovascular death at 1 year. The 6MWT should be
further examined in the general population of patients
undergoing TAVR as a marker for survival after the
procedure. Frail, immobile patients may be considered for
medical therapy only.
TAVR and futility. Although TAVR improves quality of
life and is cost effective (17,41) in the general population of
high-risk AS patients, there is a sizeable group of patients in
whom clinical status does not improve after a seemingly
successful TAVR procedure (4–6,9). It is conceivable that in
some severe AS patients with numerous comorbidities,
mechanical correction of their valve pathology will not result
in improvement of their well-being; for them, TAVR is
medically futile (42). Several studies have attempted to
deﬁne frailty as a marker for high surgical risk, suggesting
TAVR as a better treatment approach (43,44). It is also
likely, however, that many frail patients will not improve
after TAVR. Interestingly, in the current study, several
parameters found to be independent correlates for mortality
in CLD patients undergoing TAVR are also considered as
“frailty parameters,” including poor patient mobility and low
BMI. Low BMI is a well-recognized risk factor in the
general population of CLD patients (32). It is impossible to
deﬁne clinical futility in a large population and each indi-
vidual patient should be speciﬁcally evaluated. It appears,
however, that many frail and immobile CLD patients do not
gain signiﬁcant improvement after TAVR.
Clinical implications. The importance of a careful pre-
operative evaluation of CLD patients undergoing evaluation
for TAVR cannot be overestimated (45,46). A heart-team
discussion, which includes a pulmonologist, should balance
the potential risks and beneﬁts for the individual patient as
well as the plan for perioperative management. The clinical
manifestations of CLD and AS are occasionally similar (47).
Up-to-date lung function evaluation and laboratory B-type
natriuretic peptide levels could assist in identifying symptom
etiology (48). For individual CLD patients with markers for
poor outcome after TAVR, such as oxygen dependency or
immobility, TAVR should be offered only after discussing
the propensity for clinical beneﬁt. Very high-risk lung
disease patients, for whom symptom etiology is unclear,
could be considered for balloon aortic valvuloplasty, for both
temporary support and in order to test for symptom etiology
(49,50). CLD patients who have clinically improved after
valvuloplasty can be expected to have a sustained improve-
ment after TAVR. When TAVR is considered in CLDpatients, optimal respiratory status should be reached before
the procedure. Short-term pulmonary rehabilitation and
inspiratory muscle training could be offered to selected
severe CLD patients before TAVR as well (46,51). Addi-
tionally, although data are lacking, performing TAVR with
a “minimalist approach,” using light sedation only, rather
than general anesthesia, could be a superior therapeutic
approach in lung disease patients (52,53).
Study limitations. Although the PARTNER trial is
a prospective, randomized trial, the current study is a post-
hoc subanalysis. Nevertheless, the comparisons of TAVR
treatment versus control included CLD patients with very
similar baseline characteristics, as shown in Table 1. Addi-
tionally, the majority of TAVR procedures included in the
PARTNER trial were performed under general anesthesia.
CLD patients undergoing TAVR under conscious sedation
may produce different clinical outcomes. Finally, the study
was limited by a lack of data on the degree of patient airﬂow
obstruction at baseline. Yet, all patients included in the
PARTNER trial were presented and adjudicated during
conference calls with the executive committee and other
investigators. During these presentations, data on lung
disease severity is commonly discussed and pulmonologists
are usually part of the heart-team decision making. In
addition, it should be noted that pulmonary function test
interpretation is very limited in congestive heart failure
patients (54) and mean FEV1 improves by up to 35% and
may return to normal only by diuresis in these patients (55).
Moreover, a recently published paper revealed that pulmo-
nary function tests commonly improve after aortic valve
replacement surgery (56). Interpretation of pulmonary
function tests is even more challenging in frail, elderly
patients, such as those included in the PARTNER trial (the
majority are octogenarians). Furthermore, it has been found
that the degree of airﬂow obstruction in CLD patients is not
as effective a predictor for clinical outcome as are other
parameters, such as patient mobility (32).Conclusions
Although CLD patients undergoing TAVR have worse
outcomes than patients without CLD, TAVR is better
in these patients than standard therapy and is similar to
SAVR. Therefore, patients with combined severe AS
and CLD should generally be considered for TAVR in
a similar way to other high-risk patients. However,
CLD patients who are either oxygen-dependent or have
very limited mobility have poor outcomes after the
procedure and performing TAVR in these cases may be
futile.
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